iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings, Inc. reported insider equity activity by Chief Medical/Scientific Officer and EVP Advanced Technology Minang Turakhia. On August 7, 2026, he acquired 13,589 shares of common stock at $0.00 per share upon the Compensation & Human Capital Management Committee determining that performance conditions were met for previously granted performance RSUs from August 7, 2023. On August 10, 2026, he sold 7,093 shares of common stock at an average price of $124.6512 per share; these shares were sold to cover tax withholding and remittance obligations related to the vesting of the performance RSUs.
iRhythm Holdings, Inc. agreed to acquire Vital Connect, Inc. through a merger in which a wholly owned subsidiary will combine with Vital Connect, which will become an indirect wholly owned subsidiary. Eligible Target equity holders are to receive $237.5 million in cash plus $50 million in iRhythm common stock, subject to customary adjustments, with a portion of the consideration held in escrow. The number of iRhythm shares issued will be based on the 30-day volume‑weighted average trading price prior to signing.
The acquisition is expected to close by the end of 2026, subject to Target stockholder approval, expiration or termination of the Hart‑Scott‑Rodino waiting period, and other conditions. iRhythm agreed to a $9.0 million reverse termination fee payable to the Target if the deal ends in specified antitrust‑related circumstances and entered into an Interim Funding Agreement to provide an initial $10.0 million, with additional funding up to $30.0 million, to support Vital Connect’s operations before closing. The stock portion of the consideration will be issued in a private offering exempt from Securities Act registration under Section 4(a)(2) and/or Regulation D.
iRhythm Holdings, Inc. reported a strong second quarter for the three months ended June 30, 2026 and executed several major strategic actions. Revenue was $224.2 million, up 20.1% year over year, with gross margin of 72.8%, a 160-basis point increase. GAAP net loss narrowed to $0.4 million, while adjusted EBITDA reached $43.3 million with a 19.3% margin. Unrestricted cash, cash equivalents and marketable securities totaled $591.3 million as of June 30, 2026, and full-year 2026 guidance was raised to $880–$890 million of revenue and a 13.0–14.0% adjusted EBITDA margin.
iRhythm Technologies, Inc., a subsidiary of iRhythm Holdings, entered into a Settlement and License Agreement with Baxter under which it will make a $50 million settlement payment. Both sides receive worldwide, royalty-free, non-exclusive, fully paid-up licenses to specified cardiac monitoring sensor patents, along with six-year covenants not to sue and limitations on patent challenges.
Separately, iRhythm agreed to acquire VitalConnect, Inc. for approximately $287.5 million, consisting of about $237.5 million in cash funded from existing cash and $50 million in iRhythm common stock, plus up to $30 million of interim working capital financing. VitalConnect’s FDA-cleared biosensor platform is expected to broaden iRhythm’s cardiac monitoring and multi-vitals capabilities, with the transaction expected to close by the end of 2026 and to enhance revenue growth beginning in 2027 while preserving a 15% adjusted EBITDA margin target for 2027.
iRhythm Holdings, Inc. EVP Strategic Business Ops Mervin Smith reported selling 617 shares of common stock on August 3, 2026 at $122.1209 per share. The shares were sold to cover tax withholding and remittance obligations from vesting RSUs. After this sale, he directly holds 22,410 shares.
iRhythm Holdings, Inc. reported that EVP and Chief People Officer Julianne Rodda sold 2,112 shares of Common Stock on 2026-08-03 at an average price of $122.1209 per share. The shares were sold to cover tax withholding on RSU vesting, leaving her with 18,201 directly held shares.
iRhythm Holdings, Inc. reported that Chief Communications and Product Officer Chad Patterson sold 2,712 shares of common stock on 2026-08-03 at an average price of $122.1209 per share. The shares were sold to cover tax withholding and remittance obligations related to vesting Restricted Stock Units, and Patterson now directly holds 55,629 shares.
iRhythm Holdings, Inc. executive reports share sale tied to tax obligations. Chief Medical and Scientific Officer Minang Turakhia reported the sale of 1,423 shares of common stock on July 2, 2026 at an average price of $124.71 per share. A footnote explains these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. After this transaction, Turakhia directly holds 53,620 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sean Clinton Freeman, EVP of Strategy & Corporate Development, reported a sale of 918 shares of common stock at $124.71 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. After this tax-related transaction, he directly holds 13,641 shares, indicating a relatively small, routine reduction in his overall position.
iRhythm Holdings, Inc. reported a material cybersecurity incident after detecting unauthorized activity on certain third-party-hosted business applications on June 8, 2026. A threat actor later claimed to have obtained proprietary data, patient protected health information, and other personal information and demanded payment to avoid disclosure.
The company has confirmed that some data was exfiltrated but, as of this report, has not found any impact on its products, clinical or medical device systems, patient safety, operations, or financial reporting systems. The affected data was accessed via social engineering and did not involve clinical systems or individual financial account or payment card information.
iRhythm is continuing to investigate the nature and scope of the incident and the individuals affected. It currently believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations and notes that it maintains cybersecurity insurance that may cover certain losses.